Clinical Trials

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly productive contributor to clinical trials across the nation. The Beaumont Research Institute, established by the hospital’s Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training experience for the medical staff and participants in graduate medical education programs.

Auto OB Study

Status: open and not enrolling

Approval Date: 12/31/1969

The purpose of this study is to obtain information about Syngo Auto OB, a commercially available software application used on the Siemens S200 ultrasound system. This application automatically measures the fetal legs, head, abdomen and length from 2D ultrasound images. Auto OB can be turned on/off with one button.

 


Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

Status: open and enrolling

Approval Date: 12/31/1969

The purpose of this study is to find out whether a laboratory test is able to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21) and Edwards syndrome (Trisomy 18). (A “marker” is a substance in blood or tissue that can be used to show the presence of a health condition.) This study is being done to find a better marker than is currently available.


CTSU ECOG E5103: Breast Cancer

CTSU ECOG E1503: A DOUBLE-BLIND PHASE III TRIAL OF DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL WITH BEVACIZUMAB OR PLACEBO IN PATIENTS WITH LYMPH NODE POSITIVE AND HIGH RISK LYMPH NODE NEGATIVE BREAST CANCER

Status: open and enrolling

Approval Date: 12/31/1969

The purpose of this study is to determine if adding a medication by the name of bevacizumab to the current standard chemotherapy of cancer-reducing medications, namely doxorubicin, cyclophosphamide and paclitaxel, reduces the risk of recurrence (called disease-free survival) compared to standard chemotherapy alone. Bevacizumab has been approved by the FDA (Food and Drug Administration) for use in the chemotherapy treatment of patients with colorectal cancer. The outcome for those patients showed improvement with the use of this drug. In this study, Bevacizumab is considered investigational because it has not received FDA approval as yet for use in breast cancer. However, this drug has been extensively studied in previous breast cancer clinical trials. These studies showed improved results in patients whose breast cancer recurred. Based on these results, it is hoped that using this medication or this type of medication earlier in treatment of the disease may lead to better outcomes for this group of patients.


Prevalence Of Vitamin D Deficiency In Type 1 Diabetes Mellitus And Effect On Insulin Requirement After Supplementation With Vitamin D - A Pilot Study

Prevalence Of Vitamin D Deficiency In Type 1 Diabetes Mellitus And Effect On Insulin Requirement After Supplementation With Vitamin D - A Pilot Study

Status: open and enrolling

Approval Date: 12/31/1969

Vitamin D is a strong regulator of our immune system and is involved in regulating cell growth and change. Vitamin D helps in controlling normal endocrine function of the pancreas, this is done by binding to nuclear receptors. Vitamin D decreases the destruction of cells in the pancreas. By preventing cell destruction it can prevent autoimmune diabetes. Vitamin D is important for both insulin (the hormone that regulates the sugar in blood) secretion and sensitivity. Insulin secretion depends on changes in calcium. Vitamin D regulates calcium, and then the calcium helps with the insulin secretion. If the vitamin D level is too low in the blood then the balance of calcium is altered, which can interfere with insulin secretion. In current clinical practice vitamin D levels are not routinely monitored in diabetics.


Long-Term Oxygen Treatment (LOTT)

Status: closed

Approval Date: 12/31/1969

A study to determine if continuous supplemental oxygen therapy can improve survival and quality of life in patients with moderate hypoxemia, or low oxygen levels.